Could a blood test unlock a new breast cancer treatment?
NCT ID NCT01975142
First seen Dec 09, 2025 · Last updated Jun 19, 2026 · Updated 20 times
Summary
This study looked at women with metastatic breast cancer whose original tumors tested negative for HER2, a protein that some breast cancer drugs target. Researchers used a blood test to find cancer cells that had extra copies of the HER2 gene. If found, the women were treated with T-DM1, a drug that combines a HER2-targeting antibody with chemotherapy. The goal was to see if the tumor would shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Catherine de Sienne
Vandœuvre-lès-Nancy, 54519, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre Val d'Aurelle - P. Lamarque
Montpellier, 34298, France
-
Chu Saint-Louis
Paris, 75475, France
-
Chu de Limoges
Limoges, 87042, France
-
Clinique Victor Hugo
Le Mans, 72000, France
-
Institut Curie
Paris, 75005, France
-
Institut Curie - Hôpital René HUGENIN
Saint-Cloud, SAINT-CLOUD, France
-
Institut de Cancérologie HARTMANN
Levallois-Perret, 92309, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, 54519, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab emtansine (T-DM1)
What this could lead to
If successful, this could offer a new treatment option for metastatic breast cancer patients who are not currently eligible for HER2-targeted therapy.
What could go wrong
This is a Phase 2 trial with only 155 participants, so results are preliminary. The approach relies on detecting rare cancer cells in the blood, which may not always be reliable.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.